Structures by: Mazurek J.
Total: 24
C39H46O6
C39H46O6
Organic & biomolecular chemistry (2007) 5, 14 2311-2314
a=6.05200(10)Å b=23.7560(5)Å c=23.9440(5)Å
α=90.00° β=90.00° γ=90.00°
(Rs)-(+)-N-[(S)-1-Cyano-2-(1?,2?-dicarba-closo-dodecaboranyl)ethyl]-tert-butylsulfinamide
C9H24B10N2OS,H2O
Chemical communications (Cambridge, England) (2016) 52, 21 4064-4067
a=6.7451(3)Å b=11.1419(6)Å c=26.4844(18)Å
α=90° β=90° γ=90°
(Ss)-(+)-N-[(R)-1-Cyano-2-(1?,2?-dicarba-closo-dodecaboranyl)ethyl]-tert-butylsulfinamide
C9H24B10N2OS
Chemical communications (Cambridge, England) (2016) 52, 21 4064-4067
a=26.2252(15)Å b=6.7734(3)Å c=11.5919(6)Å
α=90° β=115.831(3)° γ=90°
Cinnamic acid 3-nitrobenzamide co-crystal
C9H8O2,C7H6N2O3
CrystEngComm (2011) 13, 8 2817
a=6.9358(5)Å b=7.3424(4)Å c=16.7449(9)Å
α=90.167(7)° β=100.702(5)° γ=116.683(2)°
Bis(oxonium) ethane-1,2-disulfonate
2(H3O),C2H4O6S22
Acta Crystallographica Section E (2019) 75, 11 1586-1589
a=5.0371(3)Å b=5.5424(2)Å c=8.8188(4)Å
α=98.426(5)° β=104.511(3)° γ=91.663(4)°
Ethane-1,2-disulfonate monohydrate
2(H3O),C2H4O6S22
Acta Crystallographica Section E (2019) 75, 11 1586-1589
a=5.8050(3)Å b=8.3566(6)Å c=8.7433(6)Å
α=90° β=95.148(4)° γ=90°
Hydromorphone form I
C17H19NO3
Acta Crystallographica Section E (2016) 72, 5 730-733
a=8.9497(6)Å b=11.0906(6)Å c=14.2608(9)Å
α=90° β=90° γ=90°
Hydromorphone Form II
C17H19NO3
Acta Crystallographica Section E (2016) 72, 5 730-733
a=8.8802(6)Å b=10.6208(8)Å c=14.4733(9)Å
α=90° β=90° γ=90°
3-acetamido-2-nitrobenzyl acetate
C11H12N2O5
Acta Crystallographica Section C (1998) 54, 6 863-867
a=4.851(4)Å b=6.288(5)Å c=9.781(8)Å
α=99.96(7)° β=101.26(7)° γ=91.04(7)°
3-Acetamido-6-nitrobenzyl acetate
C11H12N2O5
Acta Crystallographica Section C (1998) 54, 6 863-867
a=4.874(7)Å b=17.833(16)Å c=13.277(15)Å
α=90.° β=92.35(10)° γ=90.°
3-Acetamido-6-nitrobenzyl acetate monohydrate
C11H12N2O5.H2O
Acta Crystallographica Section C (1998) 54, 6 863-867
a=7.453(3)Å b=10.939(5)Å c=15.473(9)Å
α=90.° β=93.84(3)° γ=90.°
1-O-benzyl-β-L-arabinopyranose
C12H16O5
Acta Crystallographica Section C (1996) 52, 6 1558-1563
a=5.858(3)Å b=8.171(3)Å c=24.367(7)Å
α=90.° β=90.° γ=90.°
1-O-benzyl-3,4-O-isopropylidene-β-L-arabinopyranose
C15H20O5
Acta Crystallographica Section C (1996) 52, 6 1558-1563
a=12.565(8)Å b=5.692(3)Å c=10.584(5)Å
α=90.00° β=102.66(5)° γ=90.°
1-O-benzyl-2-O-benzoyl-3,4-O-isopropylidene-β-L-arabinopyranose
C22H24O6
Acta Crystallographica Section C (1996) 52, 6 1558-1563
a=8.106(4)Å b=11.353(6)Å c=11.546(6)Å
α=90.00° β=106.83(4)° γ=90.°
L-histidinol phosphate tetrahydrate
C6H12N3O4P,4(H2O)
Acta Crystallographica Section C (1998) 54, 4 559-561
a=9.337(8)Å b=7.597(4)Å c=9.321(6)Å
α=90.° β=104.46(7)° γ=90.°
L-histidinol phosphate tetrahydrate
C6H12N3O4P,4(H2O)
Acta Crystallographica Section C (1998) 54, 4 559-561
a=9.359(7)Å b=7.621(3)Å c=9.367(6)Å
α=90.° β=104.31(6)° γ=90.°
N-p-Tolyl-2-chloro-5-p-toluylamino-4-p-tolylamino-6-pyrimidinecarboxyamide
C27H24ClN5O2
Acta Crystallographica Section C (1996) 52, 8 2106-2111
a=7.375(2)Å b=11.888(6)Å c=14.103(6)Å
α=101.34(4)° β=94.75(3)° γ=91.20(3)°
N-p-Tolyl-2-chloro-5-p-tolouylamino-4-p-tolylamino-6-pyrimidinecarboxyamide
C27H24ClN5O2
Acta Crystallographica Section C (1996) 52, 8 2106-2111
a=11.851(6)Å b=15.298(9)Å c=27.35(2)Å
α=90.° β=90.° γ=90.°
3,4-Dihydroxybenozic acid acetonitile solvate
C7H6O4,C2H3N
Acta Crystallographica Section E (2007) 63, 7 o3289-o3289
a=6.3792(6)Å b=10.4941(8)Å c=13.7634(12)Å
α=90.00° β=99.4790(14)° γ=90.00°
Buprenorphine
C29H41NO4
Acta Crystallographica Section E (2014) 70, 6 o635
a=9.8154(6)Å b=10.4283(9)Å c=13.4508(9)Å
α=90.00° β=108.796(5)° γ=90.00°
Methyl 4-O-acetyl-2-azido-3-O-benzyl-2-deoxy-1-lactone-- D-mannopyranosyluronate
C16H17N3O7
Journal of the American Chemical Society (2009) 131, 12080-12081
a=10.914(2)Å b=7.502(2)Å c=11.151(3)Å
α=90.00° β=112.923(7)° γ=90.00°
Methyl 4-O-acetyl-2-azido-3-O-benzyl-2-deoxy-- 1-lactone-D-mannopyranosyluronate
C16H17N3O7
Journal of the American Chemical Society (2009) 131, 12080-12081
a=10.989(2)Å b=7.718(2)Å c=11.376(3)Å
α=90.00° β=115.766(7)° γ=90.00°
C15H12N2O,C6H6N2O
C15H12N2O,C6H6N2O
Crystal Growth & Design (2010) 10, 2 903
a=5.16702(8)Å b=17.6378(3)Å c=19.7370(3)Å
α=90° β=90.9461(9)° γ=90°
N-p-Tolyl-2-chloro-5-(p-chloro)-benzoylamino-4-p-tolylamino- 6-pyrimidinecarboxyamide
C26H21Cl2N5O2
Acta Crystallographica Section C (1996) 52, 8 2106-2111
a=7.411(2)Å b=11.784(2)Å c=13.989(4)Å
α=101.61(2)° β=94.29(2)° γ=92.15(2)°